SUMMARY Serum samples from 55 patients with systemic lupus erythematosus (SLE) were selected for the absence of anti-extractable nuclear antigen antibodies after routine immunodiffusion tests. These sera were immunoblotted for anti-Sm and anti-RNP antibodies on a HeLa cell nuclear extract. Ten (18%) were negative and 45 (82%) produced complex patterns: 10 (18%) suggestive of anti-Sm, three (5%) anti-RNP, and 32 (58%) a combination of anti-Sm and anti-RNP antibodies. These data were very similar to those obtained from sera from a control group of 28 SLE sera selected for positivity of anti-Sm and anti-RNP precipitins with the immunodiffusion test. IgM isotype antibodies to the D peptide were significantly more prevalent than IgG isotype antibodies, whereas antibodies to the 68 kD polypeptide were of both IgM and IgG isotypes. Sera with an anti-Sm/RNP immunoblotting pattern stemmed from a group of patients with SLE with a higher titre of anti-dsDNA antibodies. Among clinical symptoms, the incidence of haemolytic anaemia was higher in the group of patients with the anti-Sm immunoblotting profile. Patients with an anti-RNP immunoblotting profile showed a higher incidence of cutaneous symptoms. It is concluded that immunoblotting for anti-Sm or anti-RNP antibody determination is a very sensitive diagnostic tool in patients with SLE.
Patients with systemic lupus erythematosus (SLE) produce antibodies which react with various nuclear components: DNA, histones, proteins, and RNAprotein complexes such as Sm and U1RNP antigens. ' The anti-Sm antibodies are considered to be a specific marker of SLE and constitute a major serological American Rheumatism Association criterion for diagnosis.2 Anti-UlRNP antibodies have a strong association with mixed connective tissue disease but are also present in SLE, frequently associated with anti-Sm antibodies.35 Anti-Sm antibodies, however, are less frequently present in SLE sera and are found in only 10-30% when immunoAccepted for publication 26 
Results
Sera from the 55 patients with SLE without anti-Sm or anti-RNP precipitins showed a variety of immunoblot patterns of peptide reactivity (Table 1) . Thirty three sera (60%) reacted against the D peptide and 28 (51%) against the B/B' doublet. Twenty sera (36%) reacted against the 68 kD polypeptide; 14 (25%) and 17 (31%) sera reacted against the A and C peptide respectively. Ten sera Most sera produced a complex pattern suggestive of anti-Sm, anti-RNP, or anti-Sm and anti-RNP antibodies ( Table 2 ). Ten sera (18%) recognised either the B/B' doublet or the D protein and were identified as anti-Sm sera. Three sera (5%) recognised the 68 kD polypeptide, alone or in conjunction with the A or C peptide, or both, and were called anti-RNP positive sera. Finally, 32 sera (58%) recognised simultaneously the 68 kD, B/B' doublet, and D peptides as well as either the A or C peptides and were identified as anti-Sm/RNP positive sera (Fig. 1) . The control group of 28 SLE sera with Sm or Sm/RNP precipitins produced very similar immunoblot patterns of peptide reactivity (Table 2) .
At the time of sampling 47 patients (85%) were positive in the indirect immunofluorescent test on Crithidia luciliae for anti-dsDNA antibodies: 21 patients had an anti-dsDNA antibody titre over 40. Among these 21 patients, 14 (67%) produced an anti-Sm/RNP pattern on immunoblots. One third of sera with an anti-RNP or anti-Sm pattern and 20% of sera with a negative reactivity produced a similarly high titre of anti-dsDNA antibody (p=NS). Sera from patients with anti-Sm/RNP antibodies had a low anti-dsDNA antibody titre less frequently than all the other groups of sera (p<003) ( Table 3) . The B/B' polypeptides are sometimes faintly recognised by anti-RNP positive sera, however.6 In line with these previously published data we decided to designate anti-Sm as those antibodies which recognised either of the B/B' and D polypeptides, anti-RNP as those antibodies which recognised the 68 kD polypeptide or either of the A and C polypeptides, and anti-Sm/RNP as those antibodies which recognised simultaneously any of the RNP polypeptides and either of the D or B/B' polypeptides. According to Pettersson et aP4 and Van Venrooij6 it seems that anti-RNP specificities in patients with SLE are primarily composed of reactions with A and C polypeptides.
Using the immunoblotting technique in conjunction with this nomenclature, we found that 45 (82%) of the 55 SLE sera contained non-precipitating antibodies against the polypeptide components of the Sm and RNP particles: Sm polypeptides were recognised by 10 (18%) of the sera, RNP polypeptides by 3 (5%), and Sm plus RNP polypeptides by 32 (58%) of the sera.
These data are very similar to those obtained with our control group of 28 SLE sera selected for positive immunodiffusion precipitins against Sm or Sm/RNP antigens.
Our results suggest either that immunoblotting is a highly sensitive technique for detection of anti-Sm and anti-RNP antibodies or that the sensitivity of double immunodiffusion, in our hands, is poor. Recent data reported from our unit estimated the prevalence of anti-Sm precipitins in patients with SLE as 6% in 40 European Caucasians, 22% in 20 ELISAs and immunoblotting assays. Evans et al, however, were able to detect anti-UlRNP/Sm antibodies in some sera from patients with SLE that were negative for precipitin and ELISA assays.24 These data suggest but do not prove that immunoblotting may have a higher sensitivity than ELISA for the detection of anti-Sm and anti-UlRNP antibodies.
Studies concerning the clinical and serological significance of anti-Sm and anti-RNP antibodies detected by immunoblotting have shown different correlations: patients with SLE with anti-Sm/RNP antibodies have a higher titre of anti-dsDNA antibodies, a low incidence of Raynaud's syndrome, and a high incidence of haemolytic anaemia; patients with SLE with anti-RNP antibodies have a higher incidence of cutaneous manifestations. In contrast with previously published reports of the clinical significance of anti-Sm and anti-RNP precipitating antibodies in SLE,2530 we found no correlation between anti-Sm antibodies and vasculitis, renal disease, or central nervous system symptoms. Recent data using immunoblot suggested that patients with anti-Sm antibodies might have a higher incidence of renal disease.31 Our findings do not confirm this claim. Patients with anti-RNP antibodies had the same incidence of renal disease as patients with or without anti-Sm antibodies.
The reason for such discrepancies is still unclear, and further studies with more patients will be necessary to understand the prognostic value of antiSm and anti-RNP antibodies detected by immunoblotting.
Our present data suggest, however, that immunoblotting is a very sensitive method for the detection of anti-Sm and anti-RNP antibodies in SLE and could be very useful for diagnosis of forms of SLE with little symptomatology. 
